$100.95
0.01% yesterday
Nasdaq, Aug 12, 10:00 pm CET

Amedisys, Inc. Stock price

$100.95
+3.16 3.23% 1M
+8.29 8.95% 6M
+10.16 11.19% YTD
+2.95 3.01% 1Y
-21.41 17.50% 3Y
-127.61 55.83% 5Y
+55.36 121.43% 10Y
+70.49 231.45% 20Y
Nasdaq, Closing price Tue, Aug 12 2025
-0.01 0.01%

Key metrics

Basic
Market capitalization
$3.3b
Enterprise Value
$3.3b
Net debt
$25.9m
Cash
$337.3m
Shares outstanding
32.9m
Valuation (TTM | estimate)
P/E
39.3 | 20.7
P/S
1.4 | 1.3
EV/Sales
1.4 | 1.3
EV/FCF
14.3
P/B
2.7
Financial Health
Equity Ratio
53.1%
Return on Equity
3.8%
ROCE
13.1%
ROIC
7.1%
Debt/Equity
0.3
Financials (TTM | estimate)
Revenue
$2.4b | $2.5b
EBITDA
$244.2m | $269.6m
EBIT
$226.0m | $240.8m
Net Income
$85.6m | $160.4m
Free Cash Flow
$234.2m
Growth (TTM | estimate)
Revenue
4.9% | 6.3%
EBITDA
7.9% | 18.5%
EBIT
8.1% | 14.9%
Net Income
-6.9% | 271.0%
Free Cash Flow
164.7%
Margin (TTM | estimate)
Gross
43.2%
EBITDA
10.2% | 10.8%
EBIT
9.4%
Net
3.6% | 6.4%
Free Cash Flow
9.8%
More
EPS
$2.6
FCF per Share
$7.1
Short interest
6.9%
Employees
19k
Rev per Employee
$120.0k
Show more

Is Amedisys, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Amedisys, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

17 Analysts have issued a Amedisys, Inc. forecast:

1x Buy
6%
12x Hold
71%
4x Sell
24%

Analyst Opinions

17 Analysts have issued a Amedisys, Inc. forecast:

Buy
6%
Hold
71%
Sell
24%

Financial data from Amedisys, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
2,402 2,402
5% 5%
100%
- Direct Costs 1,365 1,365
6% 6%
57%
1,038 1,038
3% 3%
43%
- Selling and Administrative Expenses 793 793
1% 1%
33%
- Research and Development Expense - -
-
-
244 244
8% 8%
10%
- Depreciation and Amortization 18 18
6% 6%
1%
EBIT (Operating Income) EBIT 226 226
8% 8%
9%
Net Profit 86 86
7% 7%
4%

In millions USD.

Don't miss a Thing! We will send you all news about Amedisys, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Amedisys, Inc. Stock News

Negative
Seeking Alpha
9 days ago
AMED's planned merger with UnitedHealth remains on the rocks with regulatory overhang still an issue. The deal is also asymmetrically weighted in UNH's favor, with the latter up for no penalty if it fails. Not so for AMED. Aside from this, there are internal factors dragging on AMED's business performance.
Positive
The Motley Fool
13 days ago
Amedisys (AMED) Q2 Revenue Tops 5%
Neutral
GlobeNewsWire
14 days ago
BATON ROUGE, La., July 29, 2025 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three and six-month periods ended June 30, 2025.
More Amedisys, Inc. News

Company Profile

Amedisys, Inc. engages in the provision of healthcare services. It operates through the following business segments: Home Health, Hospice, and Personal Care. The Home Health segment delivers services in the homes of individuals who may be recovering from an illness, injury, or surgery. The Hospice segment provides care that is designed to provide comfort and support for those who are facing a terminal illness. The Personal Care segment gives patients assistance with the essential activities of daily living. The company was founded by William F. Borne in 1982 and is headquartered in Baton Rouge, LA.

Head office United States
CEO Richard Ashworth
Employees 19,000
Founded 1982
Website www.amedisys.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today